Skip to main content

Kresmion event archive

206 cross-asset events fired across commodity, crypto, equity, forex, macro. See also the Kresmion brief for 2026-06-18.

commodity (23)

  • highOSINT energyOIL

    OSINT: Iranian Geopolitical Tensions Escalate, Raising Regional Risk

  • highFutures price gapSI=F

    Silver bear 7.0% vs prior close ($70.70 → $65.78)

  • highCommodityGOLD

    Gold -2.82%: significant decline on the session

  • highOSINT energyOIL

    OSINT: NATO Signals Heightened European Geopolitical Tensions

  • highCommodityOIL

    Oil -3.89%: significant decline on the session

  • highOSINT energyOIL

    OSINT: US casualties in Iran campaign coincide with record‑high stock market

  • highCOT extremeSILVER

    CFTC SILVER speculators at extreme short: 52-week positioning extreme

  • highCOT extremeNATURAL GA

    CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

  • highCOT extremeBITCOIN

    CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

  • highOSINT energyOIL

    OSINT: Trump signs MOU to end Iran conflict, White House says

  • mediumCommodityOIL

    Oil -1.73%: significant decline on the session

  • mediumOSINT eventOIL

    OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

  • mediumFutures price gapPL=F

    Platinum bear 5.0% vs prior close ($1,790.70 → $1,701.80)

  • mediumFutures price gapKC=F

    Coffee bear 4.3% vs prior close ($277.85 → $265.80)

  • mediumCommodityGOLD

    Gold -2.24%: significant decline on the session

  • mediumCommodityOIL

    Oil -3.49%: significant decline on the session

  • mediumCommodityGOLD

    Gold -1.17% - significant selloff

  • mediumCrop stressZW=F

    Kansas Winter Wheat: crop water stress detected (2.3σ above baseline) - potential ZW=F supply pressure

  • mediumCommodityOIL

    Oil -3.11% - significant selloff

  • lowFutures price gapNQ=F

    Nasdaq E-mini bull 3.5% vs prior close ($29,687.50 → $30,717.00)

  • lowFutures price gapCT=F

    Cotton bull 3.2% vs prior close ($76.90 → $79.33)

  • lowFutures price gapHO=F

    Heating Oil bear 3.3% vs prior close ($3.19 → $3.09)

  • lowFutures price gapGC=F

    Gold bear 3.1% vs prior close ($4,358.90 → $4,225.30)

crypto (16)

  • highOpen interestBTC

    BTC open interest +225.2% - OI surge

  • highOpen interestETH

    ETH open interest +217.9% - OI surge

  • highOpen interestSOL

    SOL open interest +162.4% - OI surge

  • highOpen interestETH

    ETH open interest -66.5% - OI collapse

  • highOpen interestBTC

    BTC open interest -44.1% - OI collapse

  • highOpen interestSOL

    SOL open interest -63.0% - OI collapse

  • highOpen interestETH

    ETH open interest -67.2% - OI collapse

  • highOpen interestBTC

    BTC open interest +252.4% - OI surge

  • highOpen interestSOL

    SOL open interest +305.0% - OI surge

  • highDEX thin liquiditySPYx

    SPYx/USDC has $67.0M volume but only $515K liquidity - thin market, slippage risk

  • highOpen interestETH

    ETH open interest -67.3% - OI collapse

  • highOpen interestSOL

    SOL open interest +307.5% - OI surge

  • highOpen interestBTC

    BTC open interest -42.3% - OI collapse

  • mediumDEX volume vs liquidityETH

    ETH DEX volume/liquidity ratio elevated (0.53x): on-chain trade volume 0.53x liquidity

  • mediumOSINT eventCRYPTO

    OSINT: DOJ Seeks Court Block on Historic US Reparations Program

  • mediumDEX volume vs liquidityETH

    ETH DEX volume/liquidity ratio elevated (0.51x): on-chain trade volume 0.51x liquidity

equity (151)

  • highClinical trial terminatedJNJ

    Phase 3 trial terminated early - JOHNSON GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study

  • highClinical trial terminatedJNJ

    Phase 3 trial terminated early - JOHNSON Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in

  • highClinical trial terminatedLLY

    Phase 3 trial terminated early - ELI A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melano

  • highClinical trial terminatedLLY

    Phase 3 trial terminated early - ELI A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic

  • highClinical trial terminatedBMY

    Phase 3 trial terminated early - BRISTOL A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus S

  • highClinical trial terminatedBIIB

    Phase 3 trial terminated early - BIOGEN A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared

  • highClinical trial terminatedBIIB

    Phase 3 trial terminated early - BIOGEN Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Pati

  • highClinical trial terminatedBIIB

    Phase 3 trial terminated early - BIOGEN Natalizumab (Tysabri) Re-Initiation of Dosing

  • highClinical trial terminatedAMGN

    Phase 3 trial terminated early - AMGEN Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Stati

  • highClinical trial terminatedAMGN

    Phase 3 trial terminated early - AMGEN AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

  • highClinical trial terminatedAMGN

    Phase 3 trial terminated early - AMGEN Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

  • highClinical trial terminatedAMGN

    Phase 3 trial terminated early - AMGEN MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

  • highClinical trial terminatedMDT

    Phase 3 trial terminated early - Medtronic Lumbar Interbody Fusion Using the Telamon® Peek™ Versus the Telamon® Hydrosorb™

  • highClinical trial terminatedABBV

    Phase 3 trial terminated early - AbbVie A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azaciti

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo f

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterole

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensa

  • highClinical trial terminatedMRK

    Phase 3 trial terminated early - Merck Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Pati

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treat

  • highClinical trial terminatedPFE

    Phase 3 trial terminated early - PFIZER A Study to Understand the Long-term Safety and Effects of an Experimental Gene T

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT Femtosecond Laser for Cataract Surgery

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascul

  • highClinical trial terminatedABT

    Phase 3 trial terminated early - ABBOTT Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral

  • highClinical trial terminatedGILD

    Phase 3 trial terminated early - GILEAD (mo)BETTA Trial in Transwomen for Optimization of ART

  • highClinical trial terminatedGILD

    Phase 3 trial terminated early - GILEAD Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic

  • highAcquisition financingKEY

    Debt issued for acquisition financing - deal likely imminent

  • highAcquisition financingNWG

    Debt issued for acquisition financing - deal likely imminent

  • highAcquisition financingBCS

    Debt issued for acquisition financing - deal likely imminent

  • highActivist stakeBNBX

    Activist 13D filing - shareholder value

  • highAcquisition financingDB

    Debt issued for acquisition financing - deal likely imminent

  • highAcquisition financingDHR

    Debt issued for acquisition financing - deal likely imminent

  • highAcquisition financingCM

    Debt issued for acquisition financing - deal likely imminent

  • mediumTrend spikePOR

    PORTLAND GENERAL ELECTRIC CO /OR/ search volume spiked +100 pts - unusual interest

  • mediumTrend spikeKLAC

    KLA CORP search volume spiked +39 pts - unusual interest

  • mediumTrend spikeLIN

    LINDE PLC search volume spiked +100 pts - unusual interest

  • mediumTrend spikeGEV

    GE Vernova Inc. search volume spiked +100 pts - unusual interest

  • mediumRSI level crossedMSFT

    MSFT RSI 18.9 - oversold (crossed below 30)

  • mediumTrend spikeMSTR

    Strategy Inc search volume spiked +26 pts - unusual interest

  • mediumEarnings below estimatesTIHRF

    Q4-2018: Missed consensus by 19.0% - EPS $0.09 vs $0.1111 estimate

  • mediumEarnings above estimatesTIHRF

    Beat consensus by 55.4% - EPS $0.157 vs $0.101 estimate

  • mediumEarnings below estimatesSPTX

    Q1-2026: Missed consensus by 95.9% - EPS $-10.34 vs $-5.2785 estimate

  • mediumEarnings below estimatesPRHI

    Missed consensus by 2109.8% - EPS $-2.87 vs $0.1428 estimate

  • mediumEarnings above estimatesPRHI

    Beat consensus by 194.1% - EPS $0.21 vs $0.0714 estimate

  • mediumEarnings below estimatesPRE

    Q1-2026: Missed consensus by 45.4% - EPS $-1.61 vs $-1.1076 estimate

  • mediumEarnings below estimatesPPIH

    Q1-2027: Missed consensus by 55.1% - EPS $0.22 vs $0.4896 estimate

  • mediumEarnings above estimatesOXM

    Q1-2027: Beat consensus by 6.9% - EPS $1.39 vs $1.3002 estimate

  • mediumEarnings above estimatesOSOPF

    Q2-2025: Beat consensus by 5.6% - EPS $0.34 vs $0.3219 estimate

  • mediumEarnings above estimatesOSOPF

    Q1-2026: Beat consensus by 10.3% - EPS $0.39 vs $0.3535 estimate

  • mediumEarnings below estimatesMRAAF

    Q3-2026: Missed consensus by 60.5% - EPS $13.91 vs $35.2563 estimate

  • mediumEarnings above estimatesMRAAF

    Q2-2026: Beat consensus by 37.7% - EPS $44.94 vs $32.6402 estimate

  • mediumEarnings above estimatesMRAAF

    Q4-2026: Beat consensus by 26.2% - EPS $42.08 vs $33.3464 estimate

  • mediumEarnings above estimatesMPNGF

    Beat consensus by 14.7% - EPS $-0.81 vs $-0.95 estimate

  • mediumEarnings above estimatesMPAA

    Q4-2026: Beat consensus by 78.3% - EPS $0.6 vs $0.3366 estimate

  • mediumEarnings above estimatesLZB

    Q4-2026: Beat consensus by 52.8% - EPS $1.26 vs $0.8248 estimate

  • mediumEarnings above estimatesGILT

    Beat consensus by 86.3% - EPS $0.19 vs $0.102 estimate

  • mediumEarnings above estimatesGILT

    Q4-2025: Beat consensus by 43.5% - EPS $0.2 vs $0.1394 estimate

  • mediumEarnings above estimatesGILD

    Q3-2025: Beat consensus by 13.7% - EPS $2.47 vs $2.1728 estimate

  • mediumEarnings above estimatesGIL

    Q1-2026: Beat consensus by 7.3% - EPS $0.43 vs $0.4006 estimate

  • mediumEarnings above estimatesGIII

    Q2-2026: Beat consensus by 168.5% - EPS $0.25 vs $0.0931 estimate

  • mediumEarnings above estimatesGIII

    Q1-2027: Beat consensus by 20.9% - EPS $-0.21 vs $-0.2655 estimate

  • mediumEarnings above estimatesGIII

    Q3-2026: Beat consensus by 15.9% - EPS $1.9 vs $1.6388 estimate

  • mediumEarnings below estimatesGIII

    Q4-2026: Missed consensus by 49.9% - EPS $0.3 vs $0.5993 estimate

  • mediumEarnings below estimatesGIGM

    Missed consensus by 1766.7% - EPS $-0.85 vs $0.051 estimate

  • mediumEarnings above estimatesGIFT

    Q2-2025: Beat consensus by 19.8% - EPS $-0.09 vs $-0.1122 estimate

  • mediumEarnings below estimatesGIFT

    Q3-2025: Missed consensus by 30.7% - EPS $-0.08 vs $-0.0612 estimate

  • mediumEarnings above estimatesGIC

    Q4-2025: Beat consensus by 7.5% - EPS $0.38 vs $0.3535 estimate

  • mediumEarnings below estimatesGIC

    Q3-2025: Missed consensus by 18.8% - EPS $0.48 vs $0.5909 estimate

  • mediumEarnings above estimatesGIC

    Q4-1999: Beat consensus by 14.2% - EPS $0.3 vs $0.2626 estimate

  • mediumEarnings above estimatesGHRS

    Beat consensus by 31.2% - EPS $-0.15 vs $-0.218 estimate

  • mediumEarnings above estimatesGHRS

    Q4-2025: Beat consensus by 16.5% - EPS $-0.23 vs $-0.2754 estimate

  • mediumEarnings below estimatesGHRS

    Q1-2026: Missed consensus by 9.8% - EPS $-0.31 vs $-0.2823 estimate

  • mediumEarnings above estimatesGHM

    Q2-2026: Beat consensus by 6.7% - EPS $0.31 vs $0.2905 estimate

  • mediumEarnings above estimatesGHM

    Q3-2026: Beat consensus by 22.8% - EPS $0.31 vs $0.2525 estimate

  • mediumEarnings above estimatesGHM

    Q3-2026: Beat consensus by 78.2% - EPS $0.45 vs $0.2525 estimate

  • mediumEarnings below estimatesGHI

    Q4-2025: Missed consensus by 253.0% - EPS $-0.17 vs $0.1111 estimate

  • mediumEarnings below estimatesGHI

    Missed consensus by 85.1% - EPS $0.03 vs $0.202 estimate

  • mediumEarnings below estimatesGHI

    Q1-2026: Missed consensus by 91.7% - EPS $0.01 vs $0.1212 estimate

  • mediumEarnings below estimatesGHI

    Q2-2025: Missed consensus by 216.8% - EPS $-0.35 vs $0.2996 estimate

  • mediumEarnings above estimatesGHG

    Q4-2023: Beat consensus by 310.2% - EPS $0.87 vs $0.2121 estimate

  • mediumEarnings above estimatesGHG

    Q2-2023: Beat consensus by 49.1% - EPS $1.25 vs $0.8383 estimate

  • mediumEarnings above estimatesGHG

    Q3-2023: Beat consensus by 21.3% - EPS $1.25 vs $1.0302 estimate

  • mediumEarnings above estimatesGHG

    Q3-2024: Beat consensus by 36.0% - EPS $0.92 vs $0.6767 estimate

  • mediumEarnings below estimatesGHC

    Q4-2025: Missed consensus by 19.3% - EPS $11.45 vs $14.1905 estimate

  • mediumEarnings above estimatesGHC

    Q1-2026: Beat consensus by 26.8% - EPS $16.79 vs $13.2411 estimate

  • mediumEarnings above estimatesGHC

    Q2-2025: Beat consensus by 40.1% - EPS $14.36 vs $10.2515 estimate

  • mediumEarnings above estimatesGHC

    Q3-2025: Beat consensus by 16.3% - EPS $13.19 vs $11.3423 estimate

  • mediumEarnings above estimatesGH

    Beat consensus by 11.9% - EPS $-0.45 vs $-0.511 estimate

  • mediumEarnings below estimatesGH

    Q4-2025: Missed consensus by 38.6% - EPS $-1 vs $-0.7217 estimate

  • mediumEarnings above estimatesENGN

    Q2-2026: Beat consensus by 10.3% - EPS $-0.43 vs $-0.4795 estimate

  • mediumEarnings above estimatesDLTH

    Q1-2027: Beat consensus by 49.7% - EPS $-0.2 vs $-0.3978 estimate

  • mediumEarnings above estimatesDHT

    Q1-2026: Beat consensus by 10.9% - EPS $0.64 vs $0.5771 estimate

  • mediumEarnings above estimatesCOMP

    Beat consensus by 120.0% - EPS $0.03 vs $-0.1497 estimate

  • mediumEarnings above estimatesCBRL

    Q3-2026: Beat consensus by 162.7% - EPS $0.29 vs $-0.4624 estimate

  • mediumEarnings below estimatesAVX

    Missed consensus by 22.3% - EPS $-113400 vs $-92718 estimate

  • mediumEarnings below estimatesAVX

    Missed consensus by 24.7% - EPS $-91800 vs $-73629 estimate

  • mediumEarnings below estimatesAVX

    Missed consensus by 14.6% - EPS $-118800 vs $-103626 estimate

  • mediumHigh-coupon bond issuedGRRR

    Bond issued at elevated rate 7.5% - credit-stress signal

  • mediumHigh-coupon bond issuedNGG

    Bond issued at elevated rate 5.405% - credit-stress signal

  • mediumHigh-coupon bond issuedAMP

    Bond issued at elevated rate 4.8% - credit-stress signal

  • mediumHigh-coupon bond issuedMCY

    Bond issued at elevated rate 6.25% - credit-stress signal

  • mediumHigh-coupon bond issuedEFSC

    Bond issued at elevated rate 6.25% - credit-stress signal

  • mediumHigh-coupon bond issuedVOD

    Bond issued at elevated rate 4.8% - credit-stress signal

  • mediumRSI level crossedMSFT

    MSFT RSI 17.5 - oversold (crossed below 30)

  • mediumEarnings below estimatesTLK

    Missed consensus by 27.1% - EPS $43.9 vs $60.231 estimate

  • mediumEarnings above estimatesRH

    Q1-2027: Beat consensus by 9.4% - EPS $-1.97 vs $-2.1741 estimate

  • mediumEarnings above estimatesRFIL

    Q2-2026: Beat consensus by 52.5% - EPS $0.14 vs $0.0918 estimate

  • mediumEarnings above estimatesPNPNF

    Q1-2026: Beat consensus by 47.2% - EPS $-0.04 vs $-0.0758 estimate

  • mediumEarnings above estimatesOPAD

    Beat consensus by 13.9% - EPS $-2.4 vs $-2.788 estimate

  • mediumEarnings above estimatesOPAD

    Beat consensus by 8.9% - EPS $-2.2 vs $-2.414 estimate

  • mediumEarnings below estimatesOPAD

    Missed consensus by 9.9% - EPS $-3.7 vs $-3.366 estimate

  • mediumEarnings above estimatesONC

    Q1-2026: Beat consensus by 109.9% - EPS $1.039 vs $0.4949 estimate

  • mediumEarnings above estimatesOLN

    Beat consensus by 6.5% - EPS $-0.58 vs $-0.6206 estimate

  • mediumEarnings above estimatesOLN

    Beat consensus by 49.7% - EPS $-0.32 vs $-0.6359 estimate

  • mediumEarnings above estimatesIDR

    Beat consensus by 211.9% - EPS $0.63 vs $0.202 estimate

  • mediumEarnings above estimatesICON

    Q1-2026: Beat consensus by 72.3% - EPS $-0.33 vs $-1.1934 estimate

  • mediumEarnings above estimatesICCM

    Beat consensus by 9.5% - EPS $-1.8 vs $-1.989 estimate

  • mediumEarnings below estimatesICCM

    Missed consensus by 17.6% - EPS $-1.8 vs $-1.53 estimate

  • mediumEarnings above estimatesIBIO

    Q3-2026: Beat consensus by 6.1% - EPS $-0.06 vs $-0.0639 estimate

  • mediumEarnings below estimatesCGC

    Q4-2026: Missed consensus by 309.7% - EPS $-0.404 vs $-0.0986 estimate

  • mediumEarnings above estimatesBARK

    Beat consensus by 108.6% - EPS $0.07 vs $-0.816 estimate

  • mediumEarnings below estimatesANAB

    Missed consensus by 198.7% - EPS $-1.84 vs $-0.6159 estimate

  • mediumLarge bond issueWOLF

    Large debt issuance - $1.3B due 2030

  • mediumHigh-coupon bond issuedJXN

    Bond issued at elevated rate 6.15% - credit-stress signal

  • mediumLarge bond issueINTU

    Large debt issuance - $1.0B at 4.95% due 2031

  • mediumLarge bond issueDTB

    Large debt issuance - $7.5B due 2058

  • mediumHigh-coupon bond issuedSHAZ

    Bond issued at elevated rate 6.0% - credit-stress signal

  • mediumHigh-coupon bond issuedPCT

    Bond issued at elevated rate 10.0% - credit-stress signal

  • mediumHigh-coupon bond issuedAES

    Bond issued at elevated rate 5.2% - credit-stress signal

  • mediumHigh-coupon bond issuedPSEC

    Bond issued at elevated rate 6.5% - credit-stress signal

  • mediumHigh-coupon bond issuedFISV

    Bond issued at elevated rate 5.15% - credit-stress signal

  • mediumHigh-coupon bond issuedEXPE

    Bond issued at elevated rate 5.5% - credit-stress signal

  • mediumHigh-coupon bond issuedMRX

    Bond issued at elevated rate 5.68% - credit-stress signal

  • mediumHigh-coupon bond issuedHCA

    Bond issued at elevated rate 5.25% - credit-stress signal

  • mediumHigh-coupon bond issuedDGX

    Bond issued at elevated rate 5.0% - credit-stress signal

  • mediumHigh-coupon bond issuedCBRE

    Bond issued at elevated rate 5.25% - credit-stress signal

  • mediumLarge bond issueNVDA

    Large debt issuance - $8.5B at 4.25% due 2028

  • mediumHigh-coupon bond issuedSCCO

    Bond issued at elevated rate 5.35% - credit-stress signal

  • mediumLarge bond issueAVGO

    Large debt issuance - $2.8B at 3.137% due 2035

  • mediumTrend spikeSNY

    Sanofi search volume spiked +77 pts - unusual interest

  • mediumTrend spikeISRG

    INTUITIVE SURGICAL INC search volume spiked +100 pts - unusual interest

  • lowEarnings above estimatesTHSGF

    Q4-2026: EPS $-0.004 vs $-0.0052 estimate, in line on a near-zero consensus

  • lowEarnings above estimatesGILT

    EPS $0.21 vs $0.034 estimate, +0.18 on a near-zero consensus

  • lowEarnings above estimatesGILT

    Q1-2026: EPS $0.18 vs $0.0408 estimate, +0.14 on a near-zero consensus

  • lowEarnings below estimatesGIGM

    Q2-2010: EPS $-0.60 vs $0.0255 estimate, -0.63 on a near-zero consensus

forex (6)

  • mediumOSINT eventFOREX

    OSINT: DOJ Seeks Court Block on Historic US Reparations Program

  • mediumOSINT eventFOREX

    OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

  • mediumDollar index moveDXY

    DXY +0.72% - dollar strength signal

  • mediumDollar index moveDXY

    DXY +0.56% - dollar strength signal

  • mediumOSINT eventFOREX

    OSINT: UK-China Steel Trade Tensions Rise Amid New Tariff Discussions

  • mediumDollar index moveDXY

    DXY +0.33% - dollar strength signal

macro (4)

  • mediumOSINT eventDEFENSE

    OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

  • mediumOSINT eventSHIPPING

    OSINT: UK-China Steel Trade Tensions Rise Amid New Tariff Discussions

  • mediumNFCI reliefMARKET

    Financial conditions loosening - NFCI at -0.51, liquidity supportive

  • mediumVIXVIX

    VIX at 18.4 - CAUTION territory